Preliminary Results that Assess Metformin Treatment in a Preclinical Model of Pancreatic Cancer Using Simultaneous [18F]FDG PET and acidoCEST MRI
- 242 Downloads
We sought to determine if the synergy between evaluations of glucose uptake in tumors and extracellular tumor acidosis measured with simultaneous positron emission tomography (PET)/magnetic resonance imaging (MRI) can improve longitudinal evaluations of the response to metformin treatment.
A standard 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET protocol that evaluates glucose uptake in tumors, and a standard acidoCEST MRI protocol that measures extracellular pH (pHe) in tumors, were simultaneously performed to assess eight vehicle-treated (control) mice and eight metformin-treated mice 1 day before treatment, 1 day after initiating daily treatment with metformin, and 7 days after initiating treatment. Longitudinal changes in SUVmax and extracellular pH (pHe) were evaluated for each treatment group, and differences in SUVmax and pHe between metformin-treated and control groups were also evaluated.
MRI acquisition protocols had little effect on the PET count rate, and the PET instrumentation had little effect on image contrast during acidoCEST MRI, verifying that [18F]FDG PET and acidoCEST MRI can be performed simultaneously. The average SUVmax of the tumor model had a significant decrease after 7 days of treatment with metformin, as expected. The average tumor pHe decreased after 7 days of metformin treatment, which reflected the inhibition of the consumption of cytosolic lactic acid caused by metformin. However, the average SUVmax of the tumor model was not significantly different between the metformin-treated and control groups after 7 days of treatment, and average pHe was also not significantly different between these groups. For comparison, the combination of average SUVmax and pHe measurements significantly differed between the treatment group and control group on Day 7.
[18F]FDG PET and acidoCEST MRI studies can be performed simultaneously. The synergistic combination of assessing glucose uptake and tumor acidosis can improve differentiation of a drug-treated group from a control group during drug treatment of a tumor model.
Key words[18F]FDG PET acidoCEST MRI PET/MRI Metformin
The authors thank Ms. Christine Howison for assistance with PET/MRI studies, and Dr. Neale Hanke for assistance in preparing the tumor model. This research was supported by NIH grants R01 CA167183 and P50 CA95060.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 4.Chen LQ, Pagel MD (2015) Evaluating pH in the extracellular tumor microenvironment using CEST MRI and other imaging methods. Adv Radiol 2015:206405. https://doi.org/10.1155/2015/206405
- 13.Akhenblit PJ, Hanke NT, Gill A, et al. (2016) Assessing metabolic changes in response to mTOR inhibition in a mantle cell lymphoma xenograft model using acidoCEST MRI. Mol Imaging 29. doi: https://doi.org/10.1177/1536012116645439
- 14.Akhenblit PJ, Howison CM, Pagel MD (2015) Assessing changes in tumor extracellular pH during metabolism-targeting therapies with acidoCEST MRI. Proc WMIC 576Google Scholar
- 15.Anemone A, Consolin L, Conti L et al (2017) In vivo evaluation of tumor acidosis for assessing the early metabolic response and onset of resistance to dichloroacetate by using magnetic resonance pH imaging. Int J Oncol 51(2):498–506. https://doi.org/10.3892/ijo.2017.4029 CrossRefPubMedGoogle Scholar
- 18.Moon BF, Jones KM, Chen LQ, Liu P, Randtke EA, Howison CM, Pagel MD (2015) A comparison of iopromide and iopamidol, two acidoCEST MRI contrast media that measure tumor extracellular pH. Contrast Media Mol Imaging 10(6):446–455. https://doi.org/10.1002/cmmi.1647 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, Thielscher A, Kneilling M, Lichy MP, Eichner M, Klingel K, Reischl G, Widmaier S, Röcken M, Nutt RE, Machulla HJ, Uludag K, Cherry SR, Claussen CD, Pichler BJ (2008) Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 14(4):459–465. https://doi.org/10.1038/nm1700 CrossRefPubMedGoogle Scholar
- 21.Goertzen AL, Stortz G, Thiessen JD et al (2016) First results from a high-resolution small animal SiPm PET insert for ET/MR imaging at 7T. IEEE Trans Nucl Med 85:22424–22433Google Scholar
- 23.Stortz G, Thiessen JD, Bishop D, Khan MS, Kozlowski P, Retière F, Schellenberg G, Shams E, Zhang X, Thompson CJ, Goertzen A, Sossi V (2017) Performance of a PET insert for high resolution small animal PET/MR imaging at 7T. J Nucl Med:jnumed.116.187666. https://doi.org/10.2967/jnumed.116.187666
- 24.Thiessen JD, Shams E, Stortz G, Schellenberg G, Bishop D, Khan MS, Kozlowski P, Retière F, Sossi V, Thompson CJ, Goertzen AL (2016) MR-compatibility of a high-resolution small animal PET insert operating inside a 7 T MRI. Phys Med Biol 61(22):7934–7956. https://doi.org/10.1088/0031-9155/61/22/7934 CrossRefPubMedGoogle Scholar
- 26.Jones KM, Randtke EA, Howison CM, Pagel MD (2014) Respiration gating and Bloch fitting improve pH measurements with acidoCEST MRI in an overian orthotopic tumor model. Proc SPIE Int Soc Opt Eng 9788:978815. https://doi.org/10.1117/12.2216418
- 32.Yousef M, Tsiani E (2017) Metformin in lung cancer: review of in vitro and in vivo animal studies. Cancers Cancers (Basel) 9(5):E45. https://doi.org/10.3390/cancers9050045
- 33.Lonardo E, Cioffi M, Sancho P et al (2013) Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One 8(10):e76518. https://doi.org/10.1371/journal.pone.0076518